These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34554891)

  • 1. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
    Marini F; Giusti F; Brandi ML
    Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
    Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
    Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
    Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
    Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.
    Xu J; Ye Z; Zhuo Q; Gao H; Qin Y; Lou X; Zhang W; Wang F; Wang Y; Jing D; Fan G; Zhang Y; Chen X; Chen J; Xu X; Yu X; Ji S
    Cancer Res; 2023 Jul; 83(13):2226-2247. PubMed ID: 36939378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
    de Wilde RF; Edil BH; Hruban RH; Maitra A
    Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
    Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
    J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
    Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
    Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
    [No Abstract]   [Full Text] [Related]  

  • 8. Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors.
    Ling C; Hong X; Xu M; Wang Y; Ma X; Cui Y; Jiang R; Cao D; Wu H; Tong A; Zhao Y; Wu W
    Eur J Endocrinol; 2022 May; 187(1):85-90. PubMed ID: 35521758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression.
    Di Domenico A; Pipinikas CP; Maire RS; Bräutigam K; Simillion C; Dettmer MS; Vassella E; Thirlwell C; Perren A; Marinoni I
    Commun Biol; 2020 Dec; 3(1):740. PubMed ID: 33288854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST
    Pedraza-Arevalo S; Ibáñez-Costa A; Blázquez-Encinas R; Branco MR; Vázquez-Borrego MC; Herrera-Martínez AD; Venegas-Moreno E; Serrano-Blanch R; Arjona-Sánchez Á; Gálvez-Moreno MA; Korbonits M; Soto-Moreno A; Gahete MD; Charalambous M; Luque RM; Castaño JP
    Mol Oncol; 2022 Feb; 16(3):764-779. PubMed ID: 34601790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
    Ohki R; Saito K; Chen Y; Kawase T; Hiraoka N; Saigawa R; Minegishi M; Aita Y; Yanai G; Shimizu H; Yachida S; Sakata N; Doi R; Kosuge T; Shimada K; Tycko B; Tsukada T; Kanai Y; Sumi S; Namiki H; Taya Y; Shibata T; Nakagama H
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2404-13. PubMed ID: 24912192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.
    Mapelli P; Aboagye EO; Stebbing J; Sharma R
    Oncogene; 2015 Aug; 34(34):4439-47. PubMed ID: 25435371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
    Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
    Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
    Assi HA; Mukherjee S; Kunz PL; Machiorlatti M; Vesely S; Pareek V; Hatoum H
    Oncologist; 2020 Feb; 25(2):e276-e283. PubMed ID: 32043766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
    Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
    Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.